125 related articles for article (PubMed ID: 20039399)
1. Somatic mutations and anti-mutated citrullinated vimentin antibodies in rheumatoid arthritis: comment on the editorial by Levesque et al.
Firestein GS
Arthritis Rheum; 2010 Jan; 62(1):303-4. PubMed ID: 20039399
[No Abstract] [Full Text] [Related]
2. Selected cyclic citrullinated peptides derived from the sequence of mutated and citrullinated vimentin (MCV) are targeted by different antibodies subclasses in patients with rheumatoid arthritis in Russian patients.
Derganova O; Martinez-Gamboa L; Egerer K; Bang H; Fredenhagen G; Roggenbuck D; Esaulenko I; Burmester GR; Chernykh T; Feist E
Clin Exp Rheumatol; 2014; 32(5):622-9. PubMed ID: 25189876
[TBL] [Abstract][Full Text] [Related]
3. Antibodies to several citrullinated antigens are enriched in the joints of rheumatoid arthritis patients.
Snir O; Widhe M; Hermansson M; von Spee C; Lindberg J; Hensen S; Lundberg K; Engström A; Venables PJ; Toes RE; Holmdahl R; Klareskog L; Malmström V
Arthritis Rheum; 2010 Jan; 62(1):44-52. PubMed ID: 20039432
[TBL] [Abstract][Full Text] [Related]
4. Comparative analysis of autoantibodies targeting peptidylarginine deiminase type 4, mutated citrullinated vimentin and cyclic citrullinated peptides in rheumatoid arthritis: associations with cytokine profiles, clinical and genetic features.
Reyes-Castillo Z; Palafox-Sánchez CA; Parra-Rojas I; Martínez-Bonilla GE; del Toro-Arreola S; Ramírez-Dueñas MG; Ocampo-Bermudes G; Muñoz-Valle JF
Clin Exp Immunol; 2015 Nov; 182(2):119-31. PubMed ID: 26149185
[TBL] [Abstract][Full Text] [Related]
5. Meta-analysis: diagnostic value of serum anti-mutated citrullinated vimentin antibodies in patients with rheumatoid arthritis.
Qin X; Deng Y; Xu J; Li TJ; Li S; Zhao JM
Rheumatol Int; 2011 Jun; 31(6):785-94. PubMed ID: 20221607
[TBL] [Abstract][Full Text] [Related]
6. Value of anti-modified citrullinated vimentin and third-generation anti-cyclic citrullinated peptide compared with second-generation anti-cyclic citrullinated peptide and rheumatoid factor in predicting disease outcome in undifferentiated arthritis and rheumatoid arthritis.
van der Linden MP; van der Woude D; Ioan-Facsinay A; Levarht EW; Stoeken-Rijsbergen G; Huizinga TW; Toes RE; van der Helm-van Mil AH
Arthritis Rheum; 2009 Aug; 60(8):2232-41. PubMed ID: 19644872
[TBL] [Abstract][Full Text] [Related]
7. Diagnostic value of anti-mutated citrullinated vimentin in comparison to anti-cyclic citrullinated peptide and anti-viral citrullinated peptide 2 antibodies in rheumatoid arthritis: an Italian multicentric study and review of the literature.
Bartoloni E; Alunno A; Bistoni O; Bizzaro N; Migliorini P; Morozzi G; Doria A; Mathieu A; Lotzniker M; Allegri F; Riccieri V; Alpini C; Gabrielli A; Tampoia M; Gerli R;
Autoimmun Rev; 2012 Sep; 11(11):815-20. PubMed ID: 22394488
[TBL] [Abstract][Full Text] [Related]
8. Comparison of anti-mutated citrullinated vimentin, anti-cyclic citrullinated peptides, anti-glucose-6-phosphate isomerase and anti-keratin antibodies and rheumatoid factor in the diagnosis of rheumatoid arthritis in Chinese patients.
Zhu T; Feng L
Int J Rheum Dis; 2013 Apr; 16(2):157-61. PubMed ID: 23773638
[TBL] [Abstract][Full Text] [Related]
9. Association of anti-citrullinated vimentin and anti-citrullinated α-enolase antibodies with subsets of rheumatoid arthritis.
Montes A; Perez-Pampin E; Calaza M; Gomez-Reino JJ; Gonzalez A
Arthritis Rheum; 2012 Oct; 64(10):3102-10. PubMed ID: 22674012
[TBL] [Abstract][Full Text] [Related]
10. Diagnostic value of anti-modified citrullinated vimentin in rheumatoid arthritis.
Maraina CH; Nurdayana AK; Rusni D; Azwany Y
Int J Rheum Dis; 2010 Oct; 13(4):335-9. PubMed ID: 21199468
[TBL] [Abstract][Full Text] [Related]
11. Value of anti-mutated citrullinated vimentin antibodies in diagnosing rheumatoid arthritis.
Sghiri R; Bouajina E; Bargaoui D; Harzallah L; Fredj HB; Sammoud S; Ghedira I
Rheumatol Int; 2008 Nov; 29(1):59-62. PubMed ID: 18496693
[TBL] [Abstract][Full Text] [Related]
12. Presence and diagnostic performances of IgA class antibodies to mutated citrullinated vimentin in rheumatoid arthritis.
Sghiri R; Khalifa O; Bouajina E; Ben Haj Slama F; Baccouche K; Ben Fredj H; Gaha R; Boukadida J
Joint Bone Spine; 2010 May; 77(3):279-80. PubMed ID: 20378382
[No Abstract] [Full Text] [Related]
13. Rheumatoid arthritis specific anti-Sa antibodies target citrullinated vimentin.
Vossenaar ER; Després N; Lapointe E; van der Heijden A; Lora M; Senshu T; van Venrooij WJ; Ménard HA
Arthritis Res Ther; 2004; 6(2):R142-50. PubMed ID: 15059278
[TBL] [Abstract][Full Text] [Related]
14. Association of anti-cyclic citrullinated peptide and anti-Sa/citrullinated vimentin autoantibodies in rheumatoid arthritis.
Rodríguez-Mahou M; López-Longo FJ; Sánchez-Ramón S; Estecha A; García-Segovia A; Rodríguez-Molina JJ; Carreño L; Fernández-Cruz E
Arthritis Rheum; 2006 Aug; 55(4):657-61. PubMed ID: 16874789
[No Abstract] [Full Text] [Related]
15. Identification of citrullinated vimentin peptides as T cell epitopes in HLA-DR4-positive patients with rheumatoid arthritis.
Feitsma AL; van der Voort EI; Franken KL; el Bannoudi H; Elferink BG; Drijfhout JW; Huizinga TW; de Vries RR; Toes RE; Ioan-Facsinay A
Arthritis Rheum; 2010 Jan; 62(1):117-25. PubMed ID: 20039411
[TBL] [Abstract][Full Text] [Related]
16. Antibodies against citrullinated vimentin in rheumatoid arthritis: higher sensitivity and extended prognostic value concerning future radiographic progression as compared with antibodies against cyclic citrullinated peptides.
Mathsson L; Mullazehi M; Wick MC; Sjöberg O; van Vollenhoven R; Klareskog L; Rönnelid J
Arthritis Rheum; 2008 Jan; 58(1):36-45. PubMed ID: 18163519
[TBL] [Abstract][Full Text] [Related]
17. Clinical evaluation of anti-mutated citrullinated vimentin by ELISA in rheumatoid arthritis.
Soós L; Szekanecz Z; Szabó Z; Fekete A; Zeher M; Horváth IF; Dankó K; Kapitány A; Végvári A; Sipka S; Szegedi G; Lakos G
J Rheumatol; 2007 Aug; 34(8):1658-63. PubMed ID: 17611988
[TBL] [Abstract][Full Text] [Related]
18. Anti-citrullinated protein antibodies in rheumatoid arthritis: as good as it gets?
Szekanecz Z; Soós L; Szabó Z; Fekete A; Kapitány A; Végvári A; Sipka S; Szücs G; Szántó S; Lakos G
Clin Rev Allergy Immunol; 2008 Feb; 34(1):26-31. PubMed ID: 18270854
[TBL] [Abstract][Full Text] [Related]
19. Antibodies against mutated citrullinated vimentin are a better predictor of disease activity at 24 months in early rheumatoid arthritis than antibodies against cyclic citrullinated peptides.
Innala L; Kokkonen H; Eriksson C; Jidell E; Berglin E; Dahlqvst SR
J Rheumatol; 2008 Jun; 35(6):1002-8. PubMed ID: 18398946
[TBL] [Abstract][Full Text] [Related]
20. The anti-mutated citrullinated vimentin response classifies patients with rheumatoid arthritis into broad and narrow responders.
Engelmann R; Brandt J; Eggert M; Karberg K; Krause A; Neeck G; Mueller-Hilke B
J Rheumatol; 2009 Dec; 36(12):2670-4. PubMed ID: 19884278
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
